Loading
IARC estimates 35,867 new cancer cases and 22,888 cancer deaths in Kenya in 2024; the commonest new cancers are breast, cervix uteri and prostate. This page is assembled automatically from OnCo's data: 8 trials with a site there, 3 institutions and 3 people, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 5,822 | 31.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 4,294 | 24.0 | Cervical cancer |
| Prostate | 3,601 | 32.2 | Prostate cancer |
| Oesophagus | 2,532 | 8.6 | Oesophageal cancer |
| Colorectum | 2,525 | 8.2 | Colorectal cancer |
| Stomach | 1,296 | 4.4 | Gastric & gastro-oesophageal junction cancer |
| Leukaemia | 1,287 | 3.1 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Trachea, bronchus and lung | 1,017 | 3.4 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Lip, oral cavity | 882 | 2.9 | |
| Non-Hodgkin lymphoma | 879 | 2.3 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Breast | 2,882 | 16.2 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 2,606 | 14.9 | Cervical cancer |
| Oesophagus | 2,353 | 8.1 | Oesophageal cancer |
| Prostate | 2,199 | 19.9 | Prostate cancer |
| Colorectum | 1,481 | 5.0 | Colorectal cancer |
| Stomach | 1,053 | 3.8 | Gastric & gastro-oesophageal junction cancer |
| Trachea, bronchus and lung | 935 | 3.2 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 875 | 2.2 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Pancreas | 806 | 2.9 | Pancreatic ductal adenocarcinoma |
| Multiple myeloma | 643 | 2.3 | Multiple myeloma |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Recruiting | Hoffmann-La Roche | 192 | 2026-09-21 | |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 198 | 2026-10-02 | |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 311 | 2026-09-14 | |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 238 | 2026-09-03 | |
lidERA NCT04961996 | Phase 3 | Active not recruiting | Hoffmann-La Roche | 622 | 2026-06-17 |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 171 | 2025-12-31 | |
KEN SHE (single-dose HPV vaccine) NCT03675256 | Phase 4 | Unknown | Massachusetts General Hospital | 3 | 2023-12-13 |
ACTG A5263/AMC 066 NCT01435018 | Phase 3 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 11 | 2021-10-20 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Kenya, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Kenya is open is on the registry page, under Contacts and Locations.
People whose main affiliation in OnCo is an institution or company in Kenya.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Kenya is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Kenya is ranked 29 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.